Clinical Study on Stopping Asthma Oral Liquid Combined with Recombinant Human InterferonΑ-1b Nebulized Inhalation for Pediatric Respiratory Syncytial Virus Infection
Objective To analyze application value of stopping asthma oral liquid and recombinant human interferon α 1b nebulization inhalation for pediatric respiratory syncytial virus(RSV)infection.Methods The paper chose 80 patients with RSV infection in Longnan City the First People's Hospital from March 2023 to May 2023,and divided them into control group(with routine treatment,n=40)and observation group(routine treatment+stopping asthma oral liquid combined with recombinant human interferon α 1b nebulized inhalation,n=40)with random number table method.Clinical symptom disappearance time(cough relief time,wheezing disappearance time,body temperature recovery time)and physiological indicators were compared before and after treatment between two groups,including blood oxygen saturation(SpO2)and oxygenation index(OI).Results Time for clinical symptom disappearance and physiological index levels in observation group after treatment were higher than control group(P<0.05).Conclusion Combination of stopping asthma oral liquid and recombinant human interferon α 1b nebulization inhalation therapy can improve clinical symptoms and respiratory function of children with respiratory syncytial virus infection effectively.
Stopping asthma oral liquidPediatric respiratory syncytial virusRecombinant human interferon α 1bImmunologic function
万方数据
维普
